Paxlovid is transitioning to the commercial market. Like COVID vaccines (more on that below), Paxlovid supplies in the United States are moving away from being bought by the federal government and ...

Coronavirus cases may surge in the coming weeks, as they have every summer since the pandemic began five years ago, experts ...

The multicomponent mRNA-1083 vaccine elicited noninferior immune responses in adult patients when compared with coadministered influenza and COVID-19 vaccines.

COVID antiviral Paxlovid to see price increase following 400% vaccine hike The new price is not set, but one analyst suggested it could be up to 5x higher.

Pfizer reported $12.5 billion in Paxlovid and COVID vaccine sales in 2023, after a $57 billion peak in 2022. The company's 2024 Super Bowl ad, which cost an estimated $14 million to place, ...

Paxlovid was linked with a 26% lower risk of long Covid, a 47% lower risk of death and a 24% lower risk of hospitalization 30 days after an initial infection.

The antiviral pill Paxlovid does not significantly reduce COVID-19 hospitalizations in vaccinated older adults, according to new research by UCLA doctors. The findings, published Thursday in a ...

$1,650 COVID-19 treatment called into question after major study In a nutshell A major study of 1.6 million seniors found that Paxlovid, while widely prescribed, did not significantly reduce COVID ...

Vaccines and treatments together offer optimal protection against covid’s severe outcomes. Each reduces the risk of hospitalization and death, though Paxlovid probably has the greater effect.

Most patients in the analysis (87.5%) had received at least two COVID-19 vaccines, potentially explaining the different outcomes compared to earlier studies in unvaccinated populations.